| He, Jie |
NCT02461043: Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Adjuvant Chemotherapy in the Treatment of the Lymph Node Positive Thoracic Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 3 | 386 | RoW | paclitaxel; cisplatin, radiation | Chinese Academy of Medical Sciences | Esophageal Cancer | 12/20 | 12/23 | | |
ADAURA2, NCT05120349: A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection |
|
|
| Active, not recruiting | 3 | 385 | Europe, Canada, Japan, US, RoW | Osimertinib, AZD9291; TAGRISSO, Placebo | AstraZeneca | Non-Small Cell Lung Cancer | 08/27 | 11/32 | | |
NCT05541445: Pembrolizumab Plus CRT Followed by Surgery in Upper ESCC |
|
|
| Recruiting | 1/2 | 40 | RoW | Pembrolizumab, IO combined therapy | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophageal Squamous Cell Carcinoma | 12/23 | 12/24 | | |
LungReal_01, NCT06255197: Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers |
|
|
| Recruiting | N/A | 60000 | RoW | | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Lung Cancer, Lung Adenocarcinoma, Lung Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer | 12/28 | 12/31 | | |
| Recruiting | N/A | 1500 | RoW | Neoadjuvant immunochemotherapy, Neoadjuvant immunotherapy, Neoadjuvant chemotherapy, Neoadjuvant platinum-based doublet chemotherapy | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Non-Small Cell Lung Cancer | 08/24 | 06/26 | | |
NCT05327517: Surgery or Chemoradiotherapy for Cervical Esophageal Cancer |
|
|
| Recruiting | N/A | 192 | RoW | Esophagectomy, Definitive chemoradiotherapy | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Cervical Esophageal Cancer | 12/28 | 12/28 | | |
| Mou, Juwei |
| No trials found |
